Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Challenges of conducting a trial of uric-acid-lowering therapy in CKD.

Badve SV, Brown F, Hawley CM, Johnson DW, Kanellis J, Rangan GK, Perkovic V.

Nat Rev Nephrol. 2011 May;7(5):295-300. doi: 10.1038/nrneph.2010.186. Epub 2011 Feb 15. Review.

PMID:
21321568
2.

Hyperuricemia, Hypertension, and Chronic Kidney Disease: an Emerging Association.

Mallat SG, Al Kattar S, Tanios BY, Jurjus A.

Curr Hypertens Rep. 2016 Oct;18(10):74. Review.

PMID:
27696189
3.

Serum uric acid levels and long-term outcomes in chronic kidney disease.

Miyaoka T, Mochizuki T, Takei T, Tsuchiya K, Nitta K.

Heart Vessels. 2014 Jul;29(4):504-12. doi: 10.1007/s00380-013-0396-0. Epub 2013 Aug 9.

PMID:
23929090
4.

Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis.

Bose B, Badve SV, Hiremath SS, Boudville N, Brown FG, Cass A, de Zoysa JR, Fassett RG, Faull R, Harris DC, Hawley CM, Kanellis J, Palmer SC, Perkovic V, Pascoe EM, Rangan GK, Walker RJ, Walters G, Johnson DW.

Nephrol Dial Transplant. 2014 Feb;29(2):406-13. doi: 10.1093/ndt/gft378. Epub 2013 Sep 15. Review.

PMID:
24042021
5.

Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis.

Kanji T, Gandhi M, Clase CM, Yang R.

BMC Nephrol. 2015 Apr 19;16:58. doi: 10.1186/s12882-015-0047-z. Review.

6.

Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.

Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N.

Arthritis Rheum. 2008 Nov 15;59(11):1540-8. doi: 10.1002/art.24209.

7.

Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD).

Sezai A, Soma M, Nakata K, Osaka S, Ishii Y, Yaoita H, Hata H, Shiono M.

J Cardiol. 2015 Oct;66(4):298-303. doi: 10.1016/j.jjcc.2014.12.017. Epub 2015 Jan 31.

8.

Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial.

Goicoechea M, Garcia de Vinuesa S, Verdalles U, Verde E, Macias N, Santos A, Pérez de Jose A, Cedeño S, Linares T, Luño J.

Am J Kidney Dis. 2015 Apr;65(4):543-9. doi: 10.1053/j.ajkd.2014.11.016. Epub 2015 Jan 13.

PMID:
25595565
9.

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.

Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E, Lademacher C.

Arthritis Res Ther. 2010;12(2):R63. doi: 10.1186/ar2978. Epub 2010 Apr 6.

10.

The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study.

Hosoya T, Kimura K, Itoh S, Inaba M, Uchida S, Tomino Y, Makino H, Matsuo S, Yamamoto T, Ohno I, Shibagaki Y, Iimuro S, Imai N, Kuwabara M, Hayakawa H.

Trials. 2014 Jan 16;15:26. doi: 10.1186/1745-6215-15-26.

11.

[Establishment of therapeutic goal and plan of gout and asymptomatic hyperuricemia].

Fujimori S.

Nihon Rinsho. 2008 Apr;66(4):729-35. Review. Japanese.

PMID:
18409523
12.

Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level.

Siu YP, Leung KT, Tong MK, Kwan TH.

Am J Kidney Dis. 2006 Jan;47(1):51-9.

PMID:
16377385
13.

Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease.

Tsuruta Y, Mochizuki T, Moriyama T, Itabashi M, Takei T, Tsuchiya K, Nitta K.

Clin Rheumatol. 2014 Nov;33(11):1643-8. doi: 10.1007/s10067-014-2745-5. Epub 2014 Jul 22.

14.

New insights into uric acid effects on the progression and prognosis of chronic kidney disease.

Filiopoulos V, Hadjiyannakos D, Vlassopoulos D.

Ren Fail. 2012;34(4):510-20. doi: 10.3109/0886022X.2011.653753. Epub 2012 Jan 20. Review.

PMID:
22260409
15.

Serum uric acid and the risk of cardiovascular and renal disease.

Borghi C, Rosei EA, Bardin T, Dawson J, Dominiczak A, Kielstein JT, Manolis AJ, Perez-Ruiz F, Mancia G.

J Hypertens. 2015 Sep;33(9):1729-41; discussion 1741. doi: 10.1097/HJH.0000000000000701. Review.

PMID:
26136207
16.

Effect of urate-lowering therapies on renal disease progression in patients with hyperuricemia.

Levy GD, Rashid N, Niu F, Cheetham TC.

J Rheumatol. 2014 May;41(5):955-62. doi: 10.3899/jrheum.131159. Epub 2014 Apr 1.

PMID:
24692523
17.

The effects of allopurinol on metabolic acidosis and endothelial functions in chronic kidney disease patients.

Bayram D, Tuğrul Sezer M, İnal S, Altuntaş A, Kıdır V, Orhan H.

Clin Exp Nephrol. 2015 Jun;19(3):443-9. doi: 10.1007/s10157-014-1012-z. Epub 2014 Aug 1.

PMID:
25082656
18.
19.

Is rasburicase an effective alternative to allopurinol for management of hyperuricemia in renal failure patients? A double blind-randomized study.

De Angelis S, Noce A, Di Renzo L, Cianci R, Naticchia A, Giarrizzo GF, Giordano F, Tozzo C, Splendiani G, De Lorenzo A.

Eur Rev Med Pharmacol Sci. 2007 May-Jun;11(3):179-84.

PMID:
17970234
20.

Prednisone in Uric Acid lowering in Symptomatic Heart Failure Patients With Hyperuricemia (PUSH-PATH) study.

Liu C, Zhao Q, Zhen Y, Gao Y, Tian L, Wang L, Ji L, Liu G, Ji Z, Liu K.

Can J Cardiol. 2013 Sep;29(9):1048-54. doi: 10.1016/j.cjca.2012.11.008. Epub 2013 Feb 6.

PMID:
23395281

Supplemental Content

Support Center